Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update. Exclusive to Share Talk, here
Share Talk Bulletin Board Heroes, Monday 23rd March 2020
Share Talk Bulletin Board Heroes, Friday 13th September 2019
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update.
Share Talk Bulletin Board Heroes, Tuesday, 20th August 2019
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update.
Share Talk Bulletin Board Heroes, Wednesday 7th August 2019
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update.
Share Talk Bulletin Board Heroes, Monday 22nd July 2019
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update.
Share Talk Bulletin Board Heroes, Monday 15th July 2019
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update. e-Therapeutics plc (ETX) GCM Resources
Share Talk Weekly Stock Market News, 13th July 2019
Key Dates For Coming Week
Share Talk Weekly Stock Market News, 8th July 2019
It was another busy week across the markets and we now have the honour of two new blogs being published on Share Talk social media outlets, Malcolm Graham-Wood who
Share Talk Bulletin Board Heroes, Monday 8th July 2019
We welcome Zak Mir back with a look at some of the most followed stocks on the small-cap London market.
OKYO Pharma (LON:OKYO) Raj Patil, Director of Research & Development Podcast
Dr. Raj Patil is Sr. Director of Research & Development at OKYO Pharma speaks to Zak Mir. Dr. Patil brings more than 25 years of academic and pharmaceutical experience in
OKYO Pharma Limited (LON:OKYO) Corporate Update
Since its inception the company (OKYO Pharma Ltd. ”OKYO”) has progressed its R&D programs focused on its assets Chemerin and BAM8.
